Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
The Christ Hospital Cancer Center Research
mi
from
Cincinnati, OH
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
The Christ Hospital Cancer Center Research
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
Providence Portland Medical Center
mi
from
Portland, OR
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
Cancer Centers of the Carolinas
mi
from
Greenville, SC
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
Center For Oncology Research & Treatment, P.A.
mi
from
Dallas, TX
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
Center For Oncology Research & Treatment, P.A.
mi
from
Dallas, TX
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
University of Washington Medical Center
mi
from
Seattle, WA
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
Local Institution
mi
from
Buenos Aires,
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
Local Institution
mi
from
Buenos Aires,
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Iowa Blood and Cancer Care
mi
from
Cedar Rapids, IA
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Iowa Blood and Cancer Care
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
St. Luke's Hospital
mi
from
Cedar Rapids, IA
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
St. Luke's Hospital
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Mercy Regional Cancer Center at Mercy Medical Center
mi
from
Cedar Rapids, IA
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Mercy Regional Cancer Center at Mercy Medical Center
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Commonwealth Hematology Oncology PC-Worcester
mi
from
Worcester, MA
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Commonwealth Hematology Oncology PC-Worcester
mi
from
Worcester, MA
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Fairview University Medical Center - University Campus
mi
from
Minneapolis, MN
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Fairview University Medical Center - University Campus
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Ellis Fischel Cancer Center at University of Missouri - Columbia
mi
from
Columbia, MO
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Ellis Fischel Cancer Center at University of Missouri - Columbia
mi
from
Columbia, MO
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Capital Region Cancer Center
mi
from
Jefferson City, MO
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Capital Region Cancer Center
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Kingsbury Center for Cancer Care at Cheshire Medical Center
mi
from
Keene, NH
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Kingsbury Center for Cancer Care at Cheshire Medical Center
mi
from
Keene, NH
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Charles R. Wood Cancer Center at Glens Falls Hospital
mi
from
Glens Falls, NY
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Charles R. Wood Cancer Center at Glens Falls Hospital
mi
from
Glens Falls, NY
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
CCOP - Hematology-Oncology Associates of Central New York
mi
from
Syracuse, NY
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
CCOP - Hematology-Oncology Associates of Central New York
mi
from
Syracuse, NY
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Community General Hospital of Greater Syracuse
mi
from
Syracuse, NY
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Community General Hospital of Greater Syracuse
mi
from
Syracuse, NY
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Wayne Radiation Oncology
mi
from
Goldsboro, NC
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Wayne Radiation Oncology
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Wilson Medical Center
mi
from
Wilson, NC
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Wilson Medical Center
mi
from
Wilson, NC
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Rhode Island Hospital
mi
from
Providence, RI
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
The Miriam Hospital (Lifespan)
mi
from
Providence, RI
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
The Miriam Hospital (Lifespan)
mi
from
Providence, RI
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Roper St. Francis Cancer Center at Roper Hospital
mi
from
Charleston, SC
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Roper St. Francis Cancer Center at Roper Hospital
mi
from
Charleston, SC
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Mountainview Medical
mi
from
Berlin, VT
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Mountainview Medical
mi
from
Berlin, VT
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Click here to add this to my saved trials
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated:  6/30/2016
Danville Regional Medical Center
mi
from
Danville, VA
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Status: Enrolling
Updated: 6/30/2016
Danville Regional Medical Center
mi
from
Danville, VA
Click here to add this to my saved trials
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated:  7/12/2016
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated: 7/12/2016
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated:  7/12/2016
Mayo Clinic
mi
from
Jacksonville, FL
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated: 7/12/2016
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated:  7/12/2016
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated: 7/12/2016
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated:  7/12/2016
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated: 7/12/2016
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated:  7/12/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated: 7/12/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated:  7/12/2016
CCOP - Wichita
mi
from
Wichita, KA
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated: 7/12/2016
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated:  7/12/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated: 7/12/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated:  7/12/2016
CentraCare Health Plaza
mi
from
Saint Cloud, MN
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated: 7/12/2016
CentraCare Health Plaza
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated:  7/12/2016
Medcenter One Health System
mi
from
Bismarck, ND
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated: 7/12/2016
Medcenter One Health System
mi
from
Bismarck, ND
Click here to add this to my saved trials
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated:  7/12/2016
Rapid City Regional Hospital
mi
from
Rapid City, SD
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated: 7/12/2016
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated:  7/12/2016
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers
Status: Enrolling
Updated: 7/12/2016
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
Illinois Oncology Research Association
mi
from
Peoria, IL
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials